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Background: In this study, high risk clinical target volumes (HR-CTVs) according to GEC-ESTRO guideline were
contoured retrospectively based on CT images taken at the time of high-dose rate intracavitary brachytherapy
(HDR-ICBT) and correlation between clinical outcome and dose of HR-CTV were analyzed.
Methods: Our study population consists of 51 patients with cervical cancer (Stages IB-IVA) treated with 50 Gy
external beam radiotherapy (EBRT) using central shield combined with 2–5 times of 6 Gy HDR-ICBT with or without
weekly cisplatin. Dose calculation was based on Manchester system and prescribed dose of 6 Gy were delivered for
point A. CT images taken at the time of each HDR-ICBT were reviewed and HR-CTVs were contoured. Doses were
converted to the equivalent dose in 2 Gy (EQD2) by applying the linear quadratic model (α/β = 10 Gy).
Results: Three-year overall survival, Progression-free survival, and local control rate was 82.4%, 85.3% and 91.7%,
respectively. Median cumulative dose of HR-CTV D90 was 65.0 Gy (52.7-101.7 Gy). Median length from tandem to
the most lateral edge of HR-CTV at the first ICBT was 29.2 mm (range, 18.0-51.9 mm). On univariate analysis, both
LCR and PFS was significantly favorable in those patients D90 for HR-CTV was 60 Gy or greater (p = 0.001 and 0.03,
respectively). PFS was significantly favorable in those patients maximum length from tandem to edge of HR-CTV at
first ICBT was shorter than 3.5 cm (p = 0.042).
Conclusion: Volume-dose showed a relationship to the clinical outcome in CT based brachytherapy for cervical
carcinoma.
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brachytherapyBackground
Standard therapy for patients with locally advanced cervical
cancer is combination of external beam radiotherapy
(EBRT) and brachytherapy with concurrent chemotherapy
[1-5]. Intracavitary brachytherapy employing intrauterine
(tandem) and vaginal (ovoid) sources based on Manchester
principles, has been the standard for many decades [6,7].
Manchester system is point-based (i.e. two-dimensional) and
uses orthogonal x-ray images for calculation and prescrip-
tion of treatment doses. This concept neglects each tumor* Correspondence: namuraka@ncc.go.jp
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unless otherwise stated.size or shape because prescribed dose is delivered to a fixed
reference points. Therefore while excellent long-term
tumor control rates can be obtained for patients with small
tumors, for larger tumors relapse rate are high [8,9]. Over
the decades, GEC-ESTRO [10,11] and ABS [12] proposed
the concept of 3D image-based brachytherapy (IGBT) for
the cervical cancer. Recently improved clinical outcomes
are reported using IGBT for the advanced cervical carcin-
omas [13-19]. GEC-ESTRO working group recommend
using MRI for determining high-risk clinical target volume
(HR-CTV) and intermediate-risk CTV (IR-CTV) because
MRI is superior to CT for delineating the normal anat-
omy of the female pelvis and for identifying cervical car-
cinoma extension [19-22]. However, practically majorityral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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time of brachytherapy treatment. In many circum-
stances CT scanners are often more widely available
than MRI, therefore Viswanathan et al. developed guide-
lines for standard contouring of HR-CTV based on CT
images [23]. From 2008 we introduced CT imaging in
gynecological brachytherapy but continued to use Man-
chester system for dose calculation. In this study, we an-
alyzed correlations between clinical outcome and dose
of HR-CTV contoured based on CT images.
Methods
Patients included in current study are females with cervical
carcinoma treated by primary radiation therapy including
brachytherapy with or without concurrent chemotherapy
from April 2008 to December 2010. As mentioned above,
our department introduced CT imaging in the process of
high-dose rate intracavitary brachytherapy (HDR-ICBT) for
cervical cancer from 2008. Sixty two patients were identified
who had CT image after insertion of brachytherapy applica-
tor and 9 patients were excluded because of having distant
disease beyond pelvis and another 2 patients were excluded
because they were treated by combination of ICBT and
interstitial brachytherapy (ISBT). Therefore current study
consisted of 51 patients. All patients underwent pelvic
examination, cystoscopy, pyeloureterography, chest X-ray/
CT, pelvic CT/magnetic resonance image (MRI), and blood
test. Maximum tumor diameters were measured based on
the CT/MRI findings. All biopsy specimens were diagnosed
in Department of Pathology of our hospital.
Treatment
Principles of management of the cervical cancer in this insti-
tute were described elsewhere [24]. The treatment policy for
locally advanced cervical cancer is concurrent chemoradia-
tion therapy (cCRT) with chemotherapy regimen of weekly
cisplatin (40 mg/m2/week) or cisplatin (50 mg/m2/3 weeks)
plus oral S-1 (80–120 mg/body/day). Concurrent chemora-
diotherapy was not performed in the patients with insuffi-
cient renal function (serum creatinine > 1.5 mg/dl) and aged
over 75 years. Supportive treatments such as blood transfu-
sions were encouraged during radiotherapy.
Radiotherapy
EBRT was delivered by 3D conformal technique with linear
accelerator (Clinac iX, Varian Medical System, Palo Alto,
CA) using 15 MV photon beam. Treatment planning was
based on CT images of 3 mm slice thickness taken by
Aquilion LB CT scanner (Toshiba Medical Systems, Japan).
The common EBRT portals included whole uterus, as well
as parametrium, upper part of vagina down to the level of
lower border of obturator foramens, and the draining pelvic
lymph nodes up to the level of the common iliac (L4/5
junction). The nodal CTV included internal (obturator andhypogastric), external, and common iliac lymph nodes as
well as presacral lymph nodes down to the level of S3. If
the primary lesion involved lower third of vagina or there
were clinically palpable metastatic inguinal nodes, inguinal
regions were also included in EBRT fields. The initial 20–40
Gy was delivered to the whole pelvis with a 4-field box and
then pelvic irradiation with a 4 cm-width of central shield
(CS) being ensued reducing organ at risk (OAR) exposure.
The initiation of CS was depend upon tumor shrinkage.
Every week tumor response was accessed by attending
radiation oncologist by physical examination. For early
responding tumor width of which was smaller than 4 cm
after having received 20 Gy of EBRT, CS was initiated. For
late responding tumor width of which was larger than 4 cm
at 20 Gy, EBRT was continued until tumor width became
smaller than 4 cm. For tumors in which response of radi-
ation was unfavorable, CS did not introduced. Total pelvic
side wall dose was 50 Gy in 25 fractions. After the CS was
inserted, HDR-ICBT was performed in 1–2 sessions/week,
but EBRT and HDR-ICBT were not carried out on the
same day. All brachytherapy was carried out by 192Ir remote
after loading system (RALS, MicroSelectron HDR™,
Nucletron, Veennendaal, The Netherlands). ICBT with tan-
dem+ ovoid applicators without shielding was performed
with a prescribed dose of 6 Gy in point A using Manchester
method. A tandem-cylinder was used in the cases with a
vaginal involvement exceeding more than one-third of total
vaginal length. At each brachytherapy session, CT image of
3 mm slice thickness was taken by a large bore CT simula-
tor (Aquilion™, Toshiba, Tokyo, Japan) situated in operating
room with the patient lying in lithotomy position with the
applicators in place. Before the acquisition of CT, bladder
was filled with 100 ml of saline. Emptiness of rectum was
checked at the time of gynecological examination before in-
sertion of the applicators. For dose calculation of ICBT,
Oncentra® (Nucletron, Veennendaal, The Netherlands) was
used. HR-CTV was determined based on CT images ac-
cording to Viswanathan’s contouring guidelines [23].
Rectum and bladder were contoured as OARs. Dose con-
straints for OARs were determined as followed; D2cc blad-
der < 90 Gy EQD2, D2cc rectum < 75 Gy EQD2. In order to
fulfill these dose constraints for OARs, tumors with insuffi-
cient response after EBRT and required 50 Gy of EBRT
without CS generally could only afford two times of brachy-
therapy sessions while tumors with sufficient response and
started CS only after 20 Gy of EBRT could undergo four or
even five times of brachytherapy sessions. The workload
with using CT-based IGBT required only additional several
minutes for contouring targets and OARs compared with
conventional X-ray based 2D planning.
Follow-up
All patients were evaluated weekly for toxicity during
radiotherapy through physical examination and blood
Table 1 Patients characteristics (n = 51)
Characteristics No. of patients
Age Median (range) 62 (28-90)
FIGO stage I/II/III/IVA 10/15/19/7
Vaginal invasion Yes 19
No 32
Parametrium invasion Yes 33
No 18








Initial tumor size (cm) 4.5 (1.8-7.7)
Pre treatment Scc (mg/dl) 7.0 (0.9-94.2)
LN lymph node.
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formed 1–3 months after radiotherapy, and physical
examination and blood tests were performed regularly
every 1–6 months.
Statistical analysis
Overall survival rate was estimated from the start of radi-
ation therapy to the date of death or of the last follow-up.
Progression-free survival rate was estimated to the date of
any disease relapse considered as an event. Patients without
relapse who died of another disease or still alive were cen-
sored at the time of death or last follow-up. Local control
rate which includes central and parametrium relapses was
considered as an event, and censored at the time of death,
non-local relapse, or last follow-up. Overall survival,
Progression-free survival, and local control rate were calcu-
lated by the Kaplan-Meier method.
For adding dose of EBRT and HDR-ICBT, the equiva-
lent dose in 2 Gy fractions (EQD2) [11] according to LQ





The parameter N indicates the number of fractions
and d the dose per fraction. For calculating tumor doses,
α/β was assumed as 10 Gy. Because after insertion of CS
most of the primary disease did not receive EBRT, EQD2
of EBRT before the initiation of CS was added to the
EQD2 of HDR-ICBT. As calculation of HDR-ICBT was
based on CT taken by each brachytherapy session, EQD2
at every fraction was calculated and added together.
The survival curves were compared by the log-rank
test. For univariate analysis, all of the variables were di-
chotomized at the median. Statistical significance was
set to less than 0.05 as usual. All of the statistical ana-
lyses were performed using SPSS Statistics version 18.0
(SAS Institute, Tokyo, Japan).
This retrospective study was approved by the institutional
review board of the National Cancer Center.
Results
Among 51 patients included in this study, 42 patients were
alive at the time of the analysis and 39 were alive without
disease recurrence (December 2012). The pretreatment
characteristics of the 51 patients are summarized in Table 1.
Treatment details were summarized in Table 2. Among 30
patients who received concurrent chemotherapy, 9 patients
received cisplatin plus S-1. The median value of EQD2 for
FIGO I/II/III/IVA was 64.55 Gy, 64.97 Gy, 64.68 Gy, and
63.35 Gy, respectively. The median follow-up length of liv-
ing entire patients was 39.2 months (range, 24.3-52.0months). Three-year Overall survival, Progression-free sur-
vival and local control rate were 82.4%, 85.3% and 91.7%,
respectively (Figure 1). At the time of analysis 39 patients
were alive without disease recurrence, while 5 patients died
because of cancer and 4 due to other reasons without any
evidence of cervical cancer. Eight out of 51 patients (15.7%)
experienced persistent disease or disease recurrence after
definitive radiotherapy (one, two, three, and two patients in
FIGO I/II/III/IVA, respectively). Two patients recurred at
only local site, 2 both local and distance simultaneously,
and 4 distant only. No one experienced regional lymph
node recurrence. Among seven FIGO stage IVA patients,
one patient experienced local recurrence and eventually
died of disease, one experienced single lung metastasis
which was successfully salvaged by six cycles of carboplatin
and paclitaxel followed by stereotactic radiation therapy for
lung metastasis, and one elderly patient died from chronic
kidney dysfunction without any evidence of disease recur-
rence. Figure 2 shows example of patient who experienced
local recurrence. Tumor extended to pelvic wall at diagno-
sis (Figure 2a). The right lateral part of HR-CTV was not
covered by isodose line of 60 Gy equivalent dose in 2 Gy
per fraction (EQD2, Figure 2b). In axial MR image 3
months after completion of treatment (Figure 2c), the per-
sistent disease was found in the area not sufficiently treated
by brachytherapy. On univariate analysis, both local control
rate and Progression-free survival was significantly favor-
able in those patients with D90 for HR-CTV equal to or
greater than 60 Gy (Figure 3; p = 0.001 and 0.03, respect-
ively). The number of patients with HR-CTV D90 < 60 Gy
and ≥ 60 Gy was 12 and 39, respectively. Median volume of
Table 2 Treatment details
EBRT* central pelvic dose (Gy) Median (range) 30 (20-50)
HDR-ICBT† dose for point A Median (range) 24 (12-30)
Applicor type Tandem + ovoid 42
Tandem + cylinder 9
Concurrent chemotheraphy Yes 30
No 21
TTT†† (days) Median (range) 42 (36-67)
Volume of HR-CTV at first ICBT (ml) Median (range) 23.3 (8.3-100.8)
Maximum diameter of HR-CTV at first ICBT (mm) Median (range) 46.9 (32.2-77.5)
Maximum length from tandem to edge of HR-CTV at first ICBT (mm) Median (range) 29.2 (18.0-51.9)
EQD2
ll of point A Median (range) 62 (52-72.3)
EQD2
ll of HR-CTV D90
** Media (range) 65.0 (52.7-101.7)
*EBRT: external beam radiation therapy.
†HDR-ICBT: high-dose rate intracavitary brachytherapy.
††TTT: total treatment time.
II EDQ2: equivalent dose in 2 Gy fractions.
**HR-CTV D90: dose covering 90% of the HR-CTV.
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group was 31.8 ml and 21.1 ml, respectively and patients
with HR-CTV D90 < 60 Gy had statistically larger volume
compared with that of patients with HR-CTV D90 ≥ 60 Gy
(p = 0.022). Three-year local control rate and Progression-
free survival for those whose HR-CTV D90 < 60 Gy was
72.9% and 64.3% whereas that of patients with HR-CTV
D90 ≥ 60 Gy was 97.3% and 91.5%, respectively. Progression-
free survival was significantly favorable in those patients
when the maximum length from tandem to the margin of
HR-CTV at first ICBT was shorter than 3.5 cm (p = 0.042).Figure 1 Kaplan-Meyer curves of local control rate (LCR),
progression survival (PFS), and overall survival (OS).Treatment related toxicities
One patient experienced sigmoid colon perforation 1
month after completion of radiotherapy which required
colostomy. Because cumulative dose for sigmoid colon
D2cc was only 43.8 Gy (EQD2, α/β = 3 Gy) and develop-
ment of the perforation was rather too early, it was im-
plausible that radiation played a major role developing
this severe morbidity. Two patients developed grade 2
proctitis and none experienced greater than grade 2 cyst-
itis or vaginitis.
Discussion
In the current study, definitive radiotherapy using trad-
itional Manchester method with or without concurrent
chemotherapy for cervical carcinoma resulted in favor-
able local control with only 4 local recurrences (7.8%).
Since the introduction of the concept of IGBT [10-12],
several improved clinical results have been reported
[13-18]. It is recommended in GEC-ESTRO working
group that MRI should be used to determine IR-CTV
and HR-CTV because of its superiority of tissue discrim-
ination over CT image [20-22,25]. However, it is even
now hard for most of brachytherapy suits to prepare
MRI instruments for the use of every brachytherapy pro-
cedure for cervical cancer. As an alternative and prac-
tical solution, Viswanathan et al. proposed a guideline to
contour HR-CTV based on CT images [23]. Current
study was to the best of our knowledge first report
which validated this CT based HR-CTV contouring
guideline in clinical practice. Schmid et al. reported in-
teresting study concerning the feasibility of transrectal
ultrasonography for identifying HR-CTV in comparison
with MRI [26]. However authors still believe utilizing
CT for brachytherapy is the most realistic solution for
Figure 2 Representative images of patient who experienced local relapse. a. Axial MR T2 weighted image before treatment. Tumor extends
to right pelvic wall. b. Axial CT image at the first session of intracavitary brachytherapy (ICBT). Tumor still extends to right pelvic wall after 40 Gy
of whole pelvic EBRT. Black arrow represents isodose line of 60 Gy (EQD2) and white arrow HR-CTV at the time of brachytherapy. c. Axial MR T2
weighted image 3 months after completion of chemoradiotherapy. Persistent disease was found in right parametrium.
Figure 3 Local control rate (LCR) and progression free survival (PFS) curve stratified by HR-CTV D90 60 Gy (EQD2). a. Local control rate
(LCR) stratified by HR-CTV D90 60 Gy (EQD2). b. Progression free survival (PFS) stratified by HR-CTV D90 60 Gy (EQD2).
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vical cancer because of its prevalence and reproducibility.
Dimopoulos et al. analyzed the relationships between
dose-volume histogram (DVH) and local control using
MRI-based IGBT for cervical cancer and found out that
the D90 for HR-CTV greater than 87 Gy resulted in ex-
cellent local control [13]. In current study, the cut-off
value of D90 was 60 Gy and it was much lower than
what Dimopoulos et al. pointed out. It has been known
that Japanese centers use lower cumulative dose sched-
ules with shorter overall treatment time (OTT) than
those of US and Europe [27,28]. Recently Toita et al.
showed the efficacy of Japanese schedule in a series of
multicenter prospective trials in which Stage I and II
with small (<4 cm) tumor diameter can be effectively
treated by BED 62 Gy10 (JAROG0401/JROSG04-2) [29]
and Stage III/IVA by BED 62–65 Gy10 at point A
(JCOG1066) [30]. Therefore it is reasonable that in
current study the cut-off value is much lower than
Vienna group. In addition 60 Gy could be used as a tar-
get dose for HR-CTV D90 in institutions which perform
IGBT with Japanese schedule. However further evidence
must be accumulated in order to validate the value of
HR-CTV D90 ≥ 60 Gy in Japanese schedule.
In current study it was revealed that PFS was signifi-
cantly favorable if the maximum length from tandem to
the margin of HR-CTV at the first ICBT was shorter
than 3.5 cm. Therefore if the maximum distance be-
tween uterine cavity and margin of HR-CTV is longer
than 3.5 cm at the first session of brachytherapy, appli-
cation of image-guided brachytherapy or combined in-
tracavitary/interstitial brachytherapy [16,31-33] would
improve clinical results.
From current study, it was demonstrated that favor-
able local control could be achieved for tumors with
HR-CTV D90 ≥ 60 Gy using conventional Manchester
method. However for tumors with delayed response after
EBRT and HR-CTV D90 could only be under 60 Gy by
Manchester method, further treatment improvement is
warranted. In this context, maximum length from tan-
dem to the rim of HR-CTV ≥ 3.5 cm could be used as a
cut-off point where ISBT would play an important role.
Currently in our institution tumors of which maximum
length from tandem to the rim of HR-CTV is longer
than 3.5 cm at the time of brachytherapy are treated by
the combination of ICBT and ISBT or ISBT alone. Im-
provement of clinical results after the introduction of
the combination of ICBT and ISBT compared with con-
ventional technique will be reported elsewhere.
This study has several limitations. This is a result from
single retrospective study with a limited follow-up period
and HR-CTV was determined based on CT images rather
than MR images. Viswanathan et al. compared CT based
and MRI based CTV and concluded that the width of CTbased CTV was larger than that of MRI [23]. Therefore
HR-CTV contoured based on CT in this study may over-
estimate the tumor volume in lateral direction. This may be
part of the reason of lower cut-off value of HR-CTV D90 in
this study. However it will take long before MRI will be
available in majority of brachytherapy suit. At present as
current standard for IGBT is based on MRI, IGBT is not so
popular after its introduction in the treatment of cervical
cancer brachytherapy because MRI itself is not prevalent
yet. Therefore it is worth accumulating evidence that IGBT
based on CT image could also achieve favorable clinical re-
sults if used properly.
Conclusions
Dose-volume relationship was found in CT-based
intracavitary brachytherapy for cervical carcinoma in
Japanese schedule. Further improvement could be ex-
pected for cervical cancers with insufficient response
after EBRT. For such tumor, ISBT would play an im-
portant role and should be investigated.
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